Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
Merus N.V. - Common Shares (MRUS)
Last merus n.v. - common shares earnings: 8/19 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/mrus
Company Research
Source: GlobeNewswire
Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation MCLA-145 as monotherapy or in combination with pembrolizumab in solid tumors initial interim clinical data selected for rapid oral session presentation MCLA-129 in NSCLC with c-MET exon 14 skipping mutations initial interim clinical data selected for poster presentation UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the acceptance of three abstracts for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois on May 31- June 4, 2024. Rapid oral presentation: Title: Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metas
Show less
Read more
Impact Snapshot
Event Time:
MRUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRUS alerts
High impacting Merus N.V. - Common Shares news events
Weekly update
A roundup of the hottest topics
MRUS
News
- Merus (NASDAQ: MRUS) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
- Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.MarketBeat
- Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024GlobeNewswire
- Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Merus (NASDAQ: MRUS) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $69.00 price target on the stock.MarketBeat
MRUS
Earnings
- 11/2/23 - Beat
MRUS
Sec Filings
- 4/11/24 - Form DEFA14A
- 4/10/24 - Form DEF
- 3/29/24 - Form PRE
- MRUS's page on the SEC website